Toni Choueiri, MD discusses a novel HIF-2alpha inhibitor called casdatifan
Results show it was well-tolerated and showed promising early clinical activity in heavily pretreated patients with clear cell renal cell carcinoma.
-
1
Casdatifan is a novel HIF-2alpha inhibitor showing promising early clinical activity in heavily pretreated clear cell renal cell carcinoma patients.
-
2
The treatment was well-tolerated, with manageable side effects, primarily anemia occurring in 36% of patients.
-
3
The disease control rate for casdatifan was over 80%, with an unconfirmed response rate up to 34% in certain dosing cohorts.
-
4
Median progression-free survival was not reached in both dosing arms of 50 mg once daily and 50 mg twice daily.
-
5
A phase three trial, Peak 1, is evaluating the combination of casdatifan and cabozantinib versus cabozantinib alone after PD-1 therapy.
